Efficacy of surfactant at different gestational ages for infants with respiratory distress syndrome.
Li Wang, Long Chen, Renjun Li...
https://pubmed.ncbi.nlm.nih.gov/26550326/Actively Recruiting
Led by The Second Affiliated Hospital of Chongqing Medical University · Updated on 2025-06-04
500
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying a prenatal prevention and treatment strategy for neonatal acute respiratory distress syndrome NARDS by developing a predictive model based on perinatal risk factors. This model uses multivariate logistic regression to identify independent prenatal risks and creates a visual nomogram for early prediction of NARDS. The study also explores the role of antenatal corticosteroids ACS in preventing and treating acute respiratory distress syndrome in near-term or full-term infants by promoting fetal lung maturation and lung fluid clearance. Pregnant women identified as having an over 80% probability of their newborn developing NARDS according to the prediction model may receive ACS intervention. Those who agree to the intervention form the experimental group and receive dexamethasone, while those who do not form the control group with no intervention. The study measures glucocorticoid levels in cord blood at birth and mRNA levels of specific lung-related proteins in nasal epithelium shortly after birth to evaluate the biological effects of ACS. Participants are monitored for the occurrence and severity of pulmonary edema and NARDS using lung ultrasound and clinical evaluation over one year. Researchers also track the mortality rate of NARDS and biological markers related to lung fluid clearance. The study spans from prenatal prediction through postnatal monitoring, aiming to establish effective early prevention and treatment methods combining prediction and ACS use.
CONDITIONS
Establishment and Evaluation of Prenatal Prevention and Treatment Strategy for NARDS
L
Li Wang, MD,PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The Second Affiliated Hospital of Chongqing Medical University
Lead Sponsor
University-Town Hospital of Chongqing Medical University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Duration of ACS administration before birth
Participants in the experimental group receive antenatal corticosteroid (ACS) intervention to help prevent neonatal acute respiratory distress syndrome (NARDS).
Duration - Up to 1 year after birth
Participants and their newborns are monitored to evaluate the incidence and severity of NARDS and pulmonary edema, as well as mortality and biological markers.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Li Wang, Long Chen, Renjun Li...
https://pubmed.ncbi.nlm.nih.gov/26550326/Kartik K Venkatesh, Wesley Jackson, Brenna L Hughes...
https://pubmed.ncbi.nlm.nih.gov/30842550/Ken Miyazaki, Madoka Furuhashi, Kaoru Ishikawa...
https://pubmed.ncbi.nlm.nih.gov/25990481/Gabriele Saccone, Vincenzo Berghella
https://pubmed.ncbi.nlm.nih.gov/27733360/Rachel M Amiya, Linda B Mlunde, Erika Ota...
https://pubmed.ncbi.nlm.nih.gov/26841022/Brock Polnaszek, Julia D López, Reece Clark...
https://pubmed.ncbi.nlm.nih.gov/31578422/Hui Liu, Jing Li, Jingyu Guo...
https://pubmed.ncbi.nlm.nih.gov/35784441/Daniele De Luca, Anton H van Kaam, David G Tingay...
https://pubmed.ncbi.nlm.nih.gov/28687343/David G Sweet, Virgilio Carnielli, Gorm Greisen...
https://pubmed.ncbi.nlm.nih.gov/27649091/Liina Süvari, Otto M Helve, M Anneli Kari...
https://pubmed.ncbi.nlm.nih.gov/32663837/The Second Affiliated Hospital of Chongqing Medical University
Lead Sponsor
University-Town Hospital of Chongqing Medical University
Collaborating Sponsor